Program launch date: 18th February 2020
A blended education program designed by Springer Healthcare IME, in collaboration with Dr Paul Cornes 
and Dr Michael Muenzberg, for all medical oncologists, specialist nurses and allied healthcare professionals (HCPs) working with patients for whom biosimilars may represent a treatment option.

Despite their promise, the uptake, and therefore benefits, of biosimilars in oncology has been slower than expected. A key barrier to their uptake is healthcare professional unfamiliarity with the  concept of biosimilarity. Despite an increase in medical education, there are several clinical and non-clinical factors that contribute to a lack of confidence among HCPs.

This program aims to provide you with a better understanding of the biosimilar development process and extrapolation of indications concept, and to help improve your confidence in prescribing biosimilars to your patients. Our goal is to focus on the key issues from your point of view in order to support you in resolving and overcoming these barriers.

This expert authored eLearning module focuses on the importance of analytical data during the development process of biosimilars. It also provides a brief overview of the data requirements for approval of these products in Europe.

Scroll to Top

Huub Schellekens

Dr Huub Schellekens MD, PhD is emeritus professor of Pharmaceutical Biotechnology at Utrecht University in the Netherlands. He studied medicine at Erasmus University in Rotterdam, The Netherlands ( 1967-1973), where he also did his training in Medical Microbiology (1976-1980) and received his PhD. in 1980.

His work focuses on the preclinical development of biopharmaceuticals and he has published more than 400 papers in peer reviewed international journals, concerning many aspects of the development of therapeutic proteins. Lately, his work has included the immunogenicity of protein drugs and the disadvantages of biosimilars and non-biologic complex drugs. He is also active in developing programs to provide affordable biopharmaceuticals in the developed world and low and middle-income countries.

Prior to joining Utrecht University, Dr Schellekens was deputy director of the Dutch Primate Center, director of Medscand Ingeny and medical microbiologist at the Reinier de Graaf Hospital, Delft, the Netherlands.


Huub Schellekens has received speaker fees from Sandoz, Pfizer, Biocon, Dr Reddy and consultant fees from Sandoz USA.